As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to EMA in 2016 about Draft Guidance: Good pharmacovigilance practices (GVP) Module V – Risk management systems (Rev 2) can be found below.